SCHEMBL3636864

SCHEMBL3636864

Cc1ccc(Nc2ccc(C(=O)O)cc2Cl)cn1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCL6 P41182 2/20 0.56
BCOR Q6W2J9 2/20 0.56
GRM5 P41594 7/20 0.52
KDM4E B2RXH2 2/20 0.47
GAA P10253 2/20 0.47
MAPT P10636 2/20 0.47
NPC1 O15118 1/20 0.47
GFER P55789 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
ALDH1A1 P00352 1/20 0.47
GLA P06280 1/20 0.47
THRB P10828 1/20 0.47
HPGD P15428 1/20 0.47
HSD17B10 Q99714 1/20 0.47
RCE1 Q9Y256 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
DHODH Q02127 4/20 0.46
AURKA O14965 1/20 0.46
CNR2 P34972 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3635819 0.89 GRM5 (0.52) BCL6BCORGRM5NPSR1KCNQ3
SCHEMBL3633506 0.87 BCL6 (0.60) BCL6BCORGRM5KDM4EGAA
SCHEMBL3628259 0.84 GRM5 (0.67) GRM5NPSR1
SCHEMBL3633497 0.79 NPC1 (0.55) GRM5KDM4EGAAMAPTNPC1
SCHEMBL27801708 0.78 EPHX2 (0.48) GRM5NPSR1KCNQ3KCNQ2
SCHEMBL27780314 0.77 NPSR1 (0.43) GRM5DHODHCNR2NPSR1
SCHEMBL3634259 0.76 GRM5 (0.67) GRM5NPSR1
SCHEMBL990937 0.75 GRM5 (0.54) GRM5MAPTNPC1SMN1; SMN2MEN1
SCHEMBL990856 0.74 HCAR3 (0.65) GRM5
SCHEMBL3629913 0.74 HDAC6 (0.51) GRM5NPC1SMN1; SMN2AURKAKCNQ3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101679299-A Nicotinic acid derivatives as modulators of metabotropic glutamate receptor-5 NOVARTIS AG 2010-03-24 CN disclosed
EP-2146969-A1 NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 Novartis Ag (CH) 2010-01-27 EP disclosed
US-20090105266-A1 Organic compounds NOVARTIS AG (CH) 2009-04-23 US disclosed
WO-2008128968-A1 NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 NOVARTIS AG (CH) 2008-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105266-A1 Organic compounds SLCO2B1, SLCO1B1, SLCO1B3 BCL6 2397/4885BCOR 2019/4885GRM5 4545/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.